-
NIDA INVEST Postdoctoral Fellowship International Scholars – Special Application Deadline: April 1, 2023
January 25, 2023 NIDA International Program is accepting applications for international postdoctoral researchers for the INVEST Drug Use and Addiction Research Fellowship. This combines postdoctoral research training in the United States with professional development activities and grant-writing guidance to form a unique program for drug use and addiction scientists. Fellowship: The 12-month INVEST fellowship provides rigorous postdoctoral research training with a NIDA grantee at a U.S. institution, professional development activities that help establish personal relationships with NIDA grantees and NIDA officials, a stipend for living and personal expenses, and an allowance to cover the cost of health insurance and professional development activities. Eligibility: INVEST applicants are required to be international researchers with a doctoral degree and a minimum of 2 years of postdoctoral experience, to have citizenship or permanent residency in a country other than the United States, and to have a proficiency in written and spoken English. INVEST Mentors: INVEST mentors must be NIDA-funded researchers in the United States. Their NIDA-funded grants must be active throughout the proposed fellowship period. Reference: Steven W. Gust, Judy McCormally, & Nei-Hyun Park (2021). Increasing evidence-based substance use interventions globally: The National Institute on Drug Abuse postdoctoral fellowships, Substance Abuse, 42(4):397-406, https://doi.org/10.1080/08897077.2021.1975874. Contact NIDA: For questions about the INVEST Postdoctoral Fellowship, contact ip@nida.nih.gov.
-
CTN & ATTC Webinar: Digital Therapeutics in the Treatment of SUD (Feb 15, 11am PT
February 15, 2023 | 11am-12:30pm PT | Register here! Digital therapeutics–software used to prevent, treat, or manage a medical disorder or disease–are redefining the future of healthcare. Digital therapeutics package an entire model of care that can be delivered with fidelity and in accordance with state-of-the-science best practices into a unified, seamless digital delivery system. Digital therapeutics have been particularly transformative in the field of substance use, mental health, and other behavioral health conditions and can markedly improve access to care, quality of care, and treatment outcomes, while reducing costs, for a wide array of audiences in diverse settings. In this presentation, Dr. Lisa A. Marsch (Dartmouth Center for Technology and Behavioral Health) will review the state of the science of digital therapeutics for behavioral health and timely opportunities to scale up access to these digital health tools via multiple paths to deployment around the world. Learning objectives 1.5 CME or CE credits available. See flyer for details on accreditation. Sponsored by the Northwest and Pacific Southwest ATTCs and the Western States Node of the NIDA CTN.
-
News from the Northeast Node: Science Series Update
January 8, 2023 Northeast Node Science Series kicks off its ’22-23 Academic Year with an in-depth review of cannabis as a potential pharmacological adjunct to MOUD In November 2022, the Northeast Node welcomed Dr. Ziva Cooper of the UCLA Center for Cannabis & Cannabinoids to kick off the Node’s ’22-23 Academic Year Science Series. Dr. Cooper’s presentation, “Cannabis and Opioids: Promising pharmacology to address the opioid epidemic?” gave a brief overview of cannabis and the pharmacology of phytocannabinoids. Preclinical studies and randomized controlled trials have examined the potential for cannabinoids to modulate opioid effects and withdrawal symptoms, opioid abuse liability, and opioid analgesia. Dr. Cooper reviewed basic cannabinoid pharmacology and the state of evidence supporting the utility of cannabinoids for opioid use disorder and as an adjunct to opioids for pain management. The recorded presentation is available to all on the Northeast Node’s website. On Thursday, February 9, 2023 (12-1pm ET), the Science Series will welcome Craig R. Rush, PhD, from the University of Kentucky as he presents “Treating Stimulant Use Disorders in the Context of the Opioid Crisis: A Review.” Please email Northeast.Node.CTN@Dartmouth.edu to join the Science Series or Northeast Node mailing lists to stay in the know about the Science Series.
-
New Articles from CTN-0049 (Project HOPE) and CTN-0073 (PROUD)
January 8, 2023 Added to the CTN Dissemination Library recently: Differential effects of patient navigation across latent profiles of barriers to care among people living with HIV and comorbid conditions.Traynor SM, et al. Journal of Clinical Medicine 2023;12:114. This paper reports on a study analyzing data from CTN-0049 (Project HOPE) to see if patient navigation interventions (with and without contingency management) are effective at increasing engagement in HIV care and viral suppression for people living with HIV. Find it in the CTN Dissemination Library. Baseline representativeness of patients in clinics enrolled in the PRimary care Opioid Use Disorders treatment (PROUD) trial: Comparison of trial and non-trial clinics in the same health systems.Wartko PD, et al. BMC Health Services Research 2022;2:1593. In this paper, researchers report on an analysis comparing patients in participating and non-participating clinics from the same health systems at baseline in the PROUD trial (CTN-0074) to see if there are any differences between patients in clinics willing and able to participate in trials and those that aren’t.
